We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Cholesterol Diagnosis Related to Breast Cancer Risk

By LabMedica International staff writers
Posted on 22 Sep 2017
Print article
Image: Histopathology of breast cancer: intraductal carcinoma, comedo type, with distended duct with intact basement membrane and central tumor necrosis (Photo courtesy of Peter Abdelmessieh, DO, MSc).
Image: Histopathology of breast cancer: intraductal carcinoma, comedo type, with distended duct with intact basement membrane and central tumor necrosis (Photo courtesy of Peter Abdelmessieh, DO, MSc).
Breast cancer is a malignancy that begins when cells grow abnormally in breast tissue. Although men can also develop breast cancer, it is much more common in women. Among women around the globe, breast cancer is the most common cancer and the fifth most common cause of cancer death. In 2012, nearly 1.7 million new cases, a quarter of all new cancer cases in women, were diagnosed worldwide.

All animal cells need cholesterol to function normally and it is an essential component of cell walls. Cholesterol is also important for making vitamin D, compounds that aid digestion, and hormones. The blood transports cholesterol around the body inside lipoproteins, which are droplets of fat covered with protein. However, having too much cholesterol in the blood is a well-established risk factor for cardiovascular conditions.

Scientists at Aston University (Birmingham, UK) collected information from over one million patients attending several hospitals in the North West of England between 2000 and 2013. They searched records from female participants aged 40 and over who were and were not diagnosed with high cholesterol at baseline (the start of the study period) and did not have breast cancer at that point. For their analysis, the team included 16,043 women who were diagnosed with high cholesterol and an age-matched group of the same number of women without high cholesterol for comparison. The average age of the women was 66 years.

The investigators found a lower proportion of the high-cholesterol group developed breast cancer, compared with the group that did not receive such a diagnosis at baseline (0.5% compared with 0.8%). Further analysis revealed significantly lower odds of breast cancer in the high-cholesterol patients (odds ratio of 0.67), compared with the patients who had not received such a diagnosis. The group that had been diagnosed with high cholesterol at baseline also had lower rates of death compared with the group that had not (13.8% compared with 23.7%). After taking into account age, ethnicity, and other factors known to influence premature death, the team found that the high-cholesterol group had significantly lower odds of death (odds ratio 0.60).

The team concluded that their large, longitudinal, retrospective study shows that diagnosis of high cholesterol has a highly protective effect on the subsequent development of breast cancer. Rahul Potluri, MD, a clinical scientist and the senior author of the study said, “If a diagnosis of high cholesterol leads to lower breast cancer rates this must either relate to something inherent in the condition or affected patients, or more likely, to treatment with widely used cholesterol lowering interventions such as statins.” The study was presented at the European Society of Cardiology ESC Congress, held August 26-30, 2017, in Barcelona, Spain.

Related Links:
Aston University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.